跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
SYMTUZA - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
SYMTUZA
Authorized
STANDARD
SYMTUZA
Janssen Inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
d24bfff2a7b8ecc0
Company
Janssen Inc
Type
Standard
Approval Details
Approval Id
d24bfff2a7b8ecc0
Drug Approval Canada Name
SYMTUZA
Product Name
SYMTUZA
Status
Marketed
Status Date
2018-04-25
Original Market Date
2018-04-25
Din
02473720
Drug Class
Human
Dosage Form
Tablet
Route Of Administration
Oral
Schedule
Prescription
Ahfs
08:18.08
Atc Original
J05AR22 EMTRICITABINE, TENOFOVIR ALAFENAMIDE, DARUNAVIR AND COBICISTAT
Atc Name
j 05 ar 22
Aig Number
0460090001
Company Name
Janssen Inc
Company Address
19 Green Belt Drive, Toronto, Ontario, Canada, M3C 1L9
Company Detail Path
/organization/janssen-inc
Company Information
Pharmaceutical Company Name
Janssen Inc
Country Name
Canada
Province Name
Ontario
City Name
north york,ontario,country_ca
Address
19 Green Belt Dr
Active Ingredients
EMTRICITABINE
200 MG
COBICISTAT
150 MG
TENOFOVIR ALAFENAMIDE (TENOFOVIR ALAFENAMIDE HEMIFUMARATE)
10 MG
DARUNAVIR (DARUNAVIR ETHANOLATE)
800 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
d24bfff2a7b8ecc0
Type
Standard
Back to Health Canada Approvals